Abstract
We conducted the present study to determine the relationship between p53-dependent apoptosis and telomerase activity in ovarian cancer cells. A human ovarian adenocarcinoma cell line, SK-OV-3 that had homozygous deletion of the p53 gene was used in this study. Wild-type p53 genes were transducted to SK-OV-3 cells with a recombinant adenovirus that contained a wild-type p53 gene (AxCAp53). IC50 to cisplatin (CDDP) was 12.9 μM for SK-OV-3 cells and 9.2 μM for p53 gene-transducted SK-OV-3 cells. The apoptotic index for cells with p53 gene transduction was significantly higher than cells without transduction. Additionally, p53 gene transduction significantly enhanced CDDP-induced apoptosis. Bax protein in SK-OV-3 cells did not differ before and after exposure to CDDP. In SK-OV-3 cells with transduction of the p53 gene, the expression of p53 and Bax proteins increased after exposure to CDDP. Expression of Bcl-xL decreased after exposure to CDDP in SK-OV-3 cells with and without transduction. The telomerase activity in SK-OV-3 cells with the p53 gene was significantly lower compared with the cells without the p53 gene. CDDP exposure did not affect telomerase activity and human telomerase reverse transcriptase (hTERT) expression in both cell lines. We suggest that the p53 gene may relate to telomerase activity, but that p53-dependent apoptosis does not affect the activity. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Akiyama M, Horiguchi YJ, Saito S, Yamada O, Mizoguchi H and Yamada H (1999) Cytostatic concentration of anticancer agents do not affect telomerase activity of leukaemic cells in vitro. Eur J Cancer 35: 309–315
Blackburn EH (1992) Telomerases. Annu Rev Biochem 61: 113–119
Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G and Thompson CB (1993) Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597–608
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254
Burger AM, Double JA and Newell DR (1997) Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur J Cancer 33: 638–644
Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, Greider CW and DePinho RA (1999) p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97: 527–538
Fritsche M, Haessler C and Brandner G (1993) Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307–318
Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirschi K, West MD, Bacchetti S, Hirte HW, Counter CM and Greider CW (1995) Telomerase, cell immortality and cancer. Cold Spring Harbor Symp Quant Biol 59: 307–315
Heid AC, Stevebs J, Livak KJ and Williams PM (1996) Real time quantitative PCR. Genome Res 6: 986–994
Henriksen R, Wilander E and Oberg K (1995) Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 72: 1324–1329
Hisatomi H, Nagao K, Kanamaru T, Endo H, Tomimatsu M and Hikij K (1999) Levels of telomerase catalytic subunit mRNA as a predictor of potential malignancy. Int J Oncol 14: 727–732
Kanamori Y, Kigawa J, Minagawa Y, Irie T, Oishi T, Shimada M, Takahashi M, Nakamura T, Sato K and Terakawa N (1998) A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells. Eur J Cancer 34: 1802–1806
Kastan MB, Canman CE and Leonard CJ (1995) p53 cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 14: 3–15
Kondo Y, Kondo S, Tanaka Y, Haqqi T, Barna BP and Cowell JK (1998) Inhibition of telomerase increases the susceptibility of human malignant, glioblastoma cells to cisplatin-induced apoptosis. Oncogene 30; 16: 2243–2248
Kusumoto M, Ogawa T, Mizumoto K, Ueno H, Niiyamai H, Sato N, Nakamura M and Tanaka M (1999) Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effects on cell cycle arrest and apoptosis in human pancreatic cancer cells. Clin Cancer Res 5: 2140–2147
Liu JP (1999) Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 13: 2091–2104
Mandal M and Kumar R (1997) Bcl-2 modulates telomerase activity. J Biol Chem 272: 14183–14187
Marone M, Scambia G, Mozzetti S, Ferrandia G, Iacovella S, DePasqua A, Benedetti Panici P and Mancuso S (1998) Bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues. Clin Cancer Res 4: 517–524
Maxwell SA, Capp D and Acosta SA (1997) Telomerase activity in immortalized endothelial cells undergoing p53-mediated apoptosis. Biochem Biophys Res Commun 241: 642–645
Mukhopadhyay T, Multani AS, Roth JA and Pathak S (1998) Reduced telomeric signals and increased telomeric associations in human lung cancer cell lines undergoing p53-mediated apoptosis. Oncogene 17: 901–906
Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Tahara E, Ide T and Ishikawa F (1998) Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 18: 65–68
Pil P and Lippard SJ (1997) Cisplatin and related drugs, pp 392–410. Academic: San Diego
Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G and Zunino F (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689–693
Sato S, Kigawa J, Minagawa Y, Okada M, Shimada M, Takahashi M, Kamazawa S and Terakawa N (1999) Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma. Cancer 86: 1307–1313
Takahashi M, Kigawa J, Minagawa Y, Itamochi H, Shimada M, Kamazawa S, Sato S, Akeshima R and Terakawa N (2000) Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells. Eur J Cancer 36: 1863–1868
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Akeshima, R., Kigawa, J., Takahashi, M. et al. Telomerase activity and p53-dependent apoptosis in ovarian cancer cells. Br J Cancer 84, 1551–1555 (2001). https://doi.org/10.1054/bjoc.2001.1812
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1812